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Background: In order to gain further insight on the crosstalk between pancreatic cancer (PDAC) and stromal cells,
we investigated interactions occurring between TGFβ1 and the inflammatory proteins S100A8, S100A9 and NT-
S100A8, a PDAC-associated S100A8 derived peptide, in cell signaling, intracellular calcium (Cai
2+) and epithelial
to mesenchymal transition (EMT). NF-κB, Akt and mTOR pathways, Cai2+ and EMT were studied in well (Capan1 and BxPC3)
and poorly differentiated (Panc1 and MiaPaCa2) cell lines.
Results: NT-S100A8, one of the low molecular weight N-terminal peptides from S100A8 to be released by PDAC-derived
proteases, shared many effects on NF-κB, Akt and mTOR signaling with S100A8, but mainly with TGFβ1. The chief effects
of S100A8, S100A9 and NT-S100A8 were to inhibit NF-κB and stimulate mTOR; the molecules inhibited Akt in Smad4-
expressing, while stimulated Akt in Smad4 negative cells. By restoring Smad4 expression in BxPC3 and silencing it in
MiaPaCa2, S100A8 and NT-S100A8 were shown to inhibit NF-κB and Akt in the presence of an intact TGFβ1 canonical
signaling pathway. TGFβ1 counteracted S100A8, S100A9 and NT-S100A8 effects in Smad4 expressing, not in Smad4
negative cells, while it synergized with NT-S100A8 in altering Cai
2+ and stimulating PDAC cell growth. The effects of
TGFβ1 on both EMT (increased Twist and decreased N-Cadherin expression) and Cai2+ were antagonized by S100A9,
which formed heterodimers with TGFβ1 (MALDI-TOF/MS and co-immuno-precipitation).
Conclusions: The effects of S100A8 and S100A9 on PDAC cell signaling appear to be cell-type and context dependent. NT-
S100A8 mimics the effects of TGFβ1 on cell signaling, and the formation of complexes between TGFβ1 with S100A9 appears
to be the molecular mechanism underlying the reciprocal antagonism of these molecules on cell signaling, Cai
2+ and EMT.
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Background
S100A8/A9, NT-S100A8 are overexpressed in PDAC
stroma when cancer cells express Smad4, suggesting that
they are linked with TGFβ1 signalling.
Results
S100A8 inhibits NF-kB and activates Akt in Smad4+, not
in Smad4- cells. NT-S100A8 mimics TGFβ1. S100A9
binds to and antagonizes TGFβ1.* Correspondence: daniela.basso@sanita.padova.it
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S100A8 signaling in PDAC cells is Smad4-dependent.
Significance
Novel interactions between S100 proteins and TGFβ1
signaling in PDAC have been identified.
Background
Pancreatic ductal adenocarcinoma (PDAC), the fourth
leading cause of cancer-related mortality in the U.S.A. and
Europe [1,2], is an extremely aggressive form of cancer [3].
When the widely known PDAC precursor, PanIN, pro-
gresses from stage I to stage III, it accumulates cellular aty-
pia and a series of genetic alterations, including activation oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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p16Ink4a and p53 [4]. As clearly demonstrated in genetically
engineered mouse models of PDAC progression, the pancre-
atic epithelium-specific expression of k-ras (KrasG12D) in-
duces PanIN lesions that can progress to PDAC, the average
latency being more than one year; K-rasG12D expression
coupled with the homozygous or heterozygous deletion of
the tumor suppressor genes p53 and/or p16Ink4a under-
lies short latency PDAC [5-7]. In humans and mice, PDAC
progression is characterized by the inactivation of the
tumor suppressor gene, Smad4 [4,8]. In most cases of
PDAC, k-ras, p16Ink4a and p53 mutations are present [8],
whereas in about 50% of cases, Smad4 inactivation due to
gene deletion or mutations associated with loss of hetero-
zygosity, is identified [9]. When Smad4 is inactivated,
PDAC is associated with widespread metastases [10] and a
poorer prognosis [11].
The transcription factor encoded by Smad4 is a central
effector of the transforming growth factor beta 1
(TGFβ1) signaling pathway [12], which is one of the 12
core signaling pathways reported to be altered in most
PDAC cases [13]. TGFβ1 is critically involved in cancer
initiation and progression through tumor cell autono-
mous signaling and interactions with the tumor microenvir-
onment [14]. Coupled with the type II TGFβ receptor,
TGFβ1 activates the type I receptor, which then triggers the
canonical and/or non-canonical pathways. In the canonical
pathway it recruits and phosphorylates receptor Smads
(Smad2 and Smad3) thus facilitating their interaction with
Smad4 and its subsequent nuclear translocation, while in
the non-canonical pathway it activates a series of signaling
cascades including Ras, PI3K and NF-κB [12,15]. The effects
of TGFβ1 stimulation vary in different settings, since the re-
sponse to this molecule is cell-type and context dependent.
In PDAC, TGFβ1 acts as a tumor suppressor by inhibiting
cancer cell growth, and as a tumor promoter by dampen-
ing host immune surveillance while inducing an epithelial
to mesenchymal transition (EMT) and a stromal expan-
sion [16-19]. EMTconfers on tumor cells a capacity to mi-
grate and metastasize [17], while stromal expansion,
which is marked in PDAC [20], creates a favorable setting
for tumor cell migration and disease progression [21,22].
The TGFβ1 molecule is a crucial component in under-
standing tumor-stromal interactions: although produced
by tumor cells, it is overexpressed by stromal cells mainly
at the invasive front area of human PDAC [23]; moreover,
in an experimental PDAC mouse model TGFβ1 was
shown to mediate cancer cell derived Cxcr2 stimulatory
effects on pancreatic fibroblasts to express Ctgf, which is
greatly involved in PDAC progression [21].
In investigating tumor-stromal interactions, particular
attention should be paid to the inflammatory proteins
S100A8 and S100A9 [24], which are encoded by genes
clustered on chromosome 1q21 [25]. This chromosomeregion [26,27] as well as S100A8/A9 TLR4 and RAGE
receptors [28-30], has been associated with cancer devel-
opment and metastasis. In PDAC, S100A8/A9 are over-
expressed by infiltrating inflammatory cells [31,32], the
levels of expression appearing to be correlated with
TGFβ1 signaling: Smad4 depletion is associated with re-
duced S100A8 (not S100A9) positive infiltrating inflam-
matory cells [31,33] and, conversely, these proteins are
expressed by PDAC cell lines only in cases of Smad4 in-
activation [34]. The existence of an interaction between
S100A8, S100A9 and the TGFβ1 canonical signaling
pathway is supported by the finding that both molecules
induce Smad1 and Smad2 phosphorylation through a
RAGE dependent mechanism [33]. Since S100A8 and
S100A9 are calcium binding proteins, the complexity of
their effects on tumor biology may depend not only on
TLR4 and/or RAGE ligation, but also on alterations in intra-
cellular calcium fluxes and/or concentrations, demonstrated
to occur in pancreatic β-cells exposed to the 14 N-terminal
aminoacid peptide of S100A8 (NT-S100A8), which we iso-
lated from PDAC tissues of patients with PDAC-associated
diabetes mellitus [34]. Variations in intracellular calcium,
critical events that regulate cancer cell proliferation and pro-
gression, may be explained by the complex effects of cal-
cium on different cancer cell signaling pathways, including
the Ca-calmodulin protein kinase cascade, Akt, mTOR and
TGFβ1 [35-40]. It is not known whether the release of NT-
S100A8 from the entire S100A8 is a PDAC-driven event
and whether these two molecules, and the S100A8 binding
partner S100A9, interact with TGFβ1 in altering PDAC sig-
naling pathways and cell biology.
The end points of the present study were therefore to
ascertain whether: 1. PDAC cells express S100A8/A9 pro-
teins and PDAC-derived proteases fragment S100A8/A9
causing the release of their N-terminal peptides, with a
special focus on NT-S100A8; 2. TGFβ1 and/or an intact
TGFβ1 signaling pathway influence the S100A8/A9 and
NT-S100A8 effects on Akt, NF-κB and mTOR signaling
pathways in PDAC cells; 3. S100A8/A9 and NT-S100A8
affect intracellular calcium fluxes in a TGFβ1 dependent
or independent manner; 4. S100A8/A9 and NT-S100A8
modify PDAC cell proliferation, apoptosis and the EMT
process directly and/or by interfering with TGFβ1 activity.
In the present study we demonstrate that NT-S100A8
and S100A8 preferentially activate mTOR in cells with
wild type Smad4 expression and NF-κB in Smad4 nega-
tive cells, and that, by forming complexes, S100A8/A9
and TGFβ1 antagonize the effects of each other on
intracellular calcium and EMT.
Results
Metastatic PDAC cell lines have high S100A8/A9 expression
A comparative quantification was made of S100A8 and
S100A9 mRNA expression by real time PCR and
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PDAC metastatic SUIT2 cell line (Table 1). Capan1
expressed high S100A8 and S100A9 mRNA levels. Mia-
PaCa2 and Panc1 did not express detectable S100A8
mRNA levels, and had a S100A9 expression 100 fold
lower than SUIT2. BxPC3 did not express detectable
levels of either S100A8 or S100A9 mRNA, while the
stable transfected BxPC3-SMAD4+ cell line (BxPC3-
SMAD4+) had S100A9 (not S100A8) expression com-
parable to that of MiaPaCa2 and Panc1 (100 fold lower than
SUIT2). S100A8/A9 receptor RAGE expression, found in all
studied cell lines, was lower in BxPC3 and Panc1 than in
Capan1 and MiaPaCa2 (Additional file 1: Figure S1).
S100A8 proteolysis is induced by pancreatic cancer cell
conditioned media
Figure 1 shows low molecular weight MALDI-TOF/MS
spectra obtained after 24 hours’ incubation at 37°C of
S100A8 in complete control culture medium, Capan1
conditioned medium (CM) and Capan1 CM obtained
after treatment with the MMPs inhibitor Ukrain [41].
On incubating S100A8 with Capan1 CM, a new peptide
was found at 2280 m/z (Figure 1D). This peptide pro-
gressively accumulated as the incubation time of S100A8
in Capan1 CM increased, the kinetic of its appearance
being inverse with respect to that of S100A8 degradation
(Figure 2). The 2280 m/z peptide was not detected when
S100A8 was incubated in Ukrain treated Capan1 CM
(Figure 1E). At MALDI-TOF-MS/MS analysis using de-
novo sequencing, the 2280 m/z peptide was identified as
the 1–19 N-terminal aminoacid sequence of S100A8
(Additional file 2: Figure S2). The 1–19 N-terminal ami-
noacid sequence of S100A8 was then synthesized and in-
cubated for 1, 2, 3, 4, 5, 6, 12 and 24 hours in the control,
Capan1 and BxPC3 CM at 37°C. At the end of all incuba-
tion times, MALDI-TOF/MS analysis was made in the
low molecular weight range (650–3000 m/z). In the pres-
ence of both BxPC3 and Capan1 CM, after 24 hours’ incu-
bation the parental 19 aminoacid peptide disappeared,
while a series of new peptides were detected, the mostTable 1 S100A8 and S100A9 mRNA relative quantification









Mean ± SD Mean ± SD
BxPC3 Absent Absent 1
Capan1 1736 ± 230 582.92 ± 18.83 1
MiaPaCa2 Absent 0.01 ± 0.000798 1
Panc1 Absent 0.01 ± 0.000997 1
BxPC3-Smad4+ Absent 0.01 ± 0.003447 1
The PDAC metastatic SUIT2 cell line was used as reference (S100A8 CT = 36.46 ±
0.34 cycles; S100A9 CT = 32.01 ± 0.53 cycles; mean ± SD from three independent
experiments, each made in duplicate).abundant being those at 1030, 1252, 1435, 1852, 1873 m/z;
two of these, at 1435 and 1852 m/z, were also detected
in the spectra from S100A8 incubated with Capan1 CM
(Figure 1D). Using the proteomic tool, FindPept, the above
listed peptides were identified as the 2–10, 10–19, 8–19,
1–16 and 3–18 aminoacid sequences of S100A8, respect-
ively. At MALDI-TOF-MS/MS analysis of the 1435 m/z
peptide, its correspondence to the 8–19 S100A8 aminoa-
cid sequence was confirmed (Additional file 3: Figure S3).
Figure 3 shows the variations over time in the abundance
of 1030 and 1435 m/z, and of the 1852 and 1873 m/z pep-
tides in BxPC3 and Capan1 CM.
Effects and interactions of S100 proteins and TGFβ1 on
NF-κB, Akt, mTOR and STAT signaling in PDAC cells
To obtain a representative picture “in vitro” of the com-
plexity of human PDAC, our study included the four pan-
creatic cancer cell lines BxPC3, Capan1, MiaPaCa2 and
Panc1, which differ in their genetic make-up, grade and
metastatic potential [42]. Using these cell lines the effects
of S100A8, S100A9 and of NT-S100A8, alone or com-
bined with TGFβ1, on NF-κB, Akt, mTOR and STAT sig-
naling pathways were evaluated. The response to insulin
stimulation was also analyzed as a reference for the PI3K
pathway. To investigate NF-κB signaling, we analyzed
IκBα phosphorylation (Figure 4) that, when enhanced, is
associated with IκBα ubiquitination and the nuclear trans-
location of NF-κB dimers, which activate the transcription
of their target genes.
S100A8, S100A9, S100A8/A9 and NT-S100A8 exerted
overlapping effects on NF-κB signaling: they reduced IκBα
phosphorylation in Capan1, MiaPaCa2 and Panc1, not in
BxPC3. TGFβ1 had no significant effects on IκBα phos-
phorylation. We then studied the Akt signaling pathway
by western blot analysis of Thr308, induced by the PI3K,
and Ser473, a target site of mTORC2 [43] (Figure 5).
S100A8, S100A9 and S100A8/A9 uniformly induced in
BxPC3, and reduced in the other cell lines, Akt Thr308
phosphorylation. These molecules, but mainly S100A8
caused also a reduced Akt Ser473 phosphorylation in
Capan1, MiaPaCa2 and Panc1 cells. NT-S100A8, similarly
to S100A8, reduced in Capan1 and MiaPaCa2 Thr308
phosphorylation, but unlike S100A8 this peptide aug-
mented in the same cell lines Ser473. TGFβ1 co-treatment
caused no relevant modification in findings for the effects
of S100 calcium binding proteins on Akt phosphorylation,
with the exception of S100A8 and NT-S100A8 effects in
Panc1 cells. mTOR signaling was then studied by analyz-
ing mTOR Ser2448, mTOR Ser2481 and S6 Ribosomal Pro-
tein (S6RP) phosphorylation (Figure 6). S100A8 and
S100A9 induced mTOR Ser2448 phosphorylation in all cell
lines and Ser2481 in BxPC3 and Capan1; S100A8/A9 in-
duced in BxPC3, MiaPaCa2 and Panc1, but reduced in
Capan1, mTOR Ser2481 and Ser2448 phosphorylation and
Figure 1 S100A8 is fragmented by PDAC cell conditioned media. MALDI-TOF/MS low-molecular weight spectra obtained after overnight
incubation of S100A8 in complete control culture medium, in Capan1 conditioned media (CM) and in Ukrain treated Capan1 CM. A: complete
control medium; B: complete control medium added with 3 μM S100A8; C: Capan1 conditioned medium; D: Capan1 conditioned medium with added
3 μM S100A8; E: Ukrain treated Capan1 conditioned medium with added 3 μM S100A8. The complete control medium was incubated at 37°C in a cell
culture incubator without cells for 96 hours with 1% FCS and 0.1% gentamycin, in the same conditions as CM. The arrow indicates the 2280 m/z peptide.
Figure 2 Degradation kinetics of S100A8 by PDAC cell conditioned media. S100A8 (3 μM) was incubated with Capan1 conditioned media
for 1, 2, 3, 4, 5, 6, 12, 24, 36 and 48 hours at 37°C before MALDI-TOF/MS analyses. The intensities of S100A8 and of the main degradation peptide
identified (2280 m/z) were normalized to total ion current (TIC). A: S100A8 TIC normalized intensities; B: 2280 m/z peptide TIC normalized intensities.
The curve kinetics were obtained by exponential fitting.
Basso et al. Cell Communication and Signaling 2014, 12:20 Page 4 of 20
http://www.biosignaling.com/content/12/1/20
Figure 3 Degradation kinetics of the 2280 m/z peptide by PDAC cell conditioned media. The 2280 m/z peptide (200 μM), encompassing
the 1–19 aminoacid sequence of S100A8, was incubated with BxPC3 (A and B) or Capan1 (C and D) conditioned media for 1, 2, 3, 4, 5, 6, 12 and
24 hours at 37°C before MALDI-TOF/MS analyses. The intensities of the main five peptides identified were normalized to total ion current (TIC). In
non-conditioned media the abundance of the parental 19 aminoacid peptide at 2280 m/z was 0.99 both at time 0 and after 24 hours.
Basso et al. Cell Communication and Signaling 2014, 12:20 Page 5 of 20
http://www.biosignaling.com/content/12/1/20induced S6RP phosphorylation in BxPC3. NT-S100A8 and
TGFβ1 had shared effects on mTOR, both molecules in-
ducing Ser2481 and Ser2448 phosphorylation in all cell lines.
In Capan1 S100A9 and TGFβ1 co-treatment abolished
mTOR Ser2481 and Ser2448 phosphorylation induced by
any of these molecules. STAT3, constitutively phosphory-
lated in all studied PDAC cell lines, was minimally affected
by S100A8/A9 and TGFβ1 co-treatment only, which re-
duced in MiaPaCa2 and induced in Panc1 Stat3 phosphor-
ylation (Additional file 4: Figure S4).
Overall the above data indicate that the S100A8, S100A9
and S100A8/A9 heterocomplex trigger the same signaling
pathways, although any molecule may evoke independent
effects depending on the PDAC cell type. S100A8, S100A9
and S100A8/A9 inhibit NF-κB and Akt in PDAC cells with
an intact Smad4, but not in cells (BxPC3) bearing Smad4
homozygous deletion. The independent actions of S100A8/
A9 heterocomplex and of S100A9 were particularly evident
in Capan1 and Panc1 cells: like S100A8 and S100A9,
S100A8/A9 inhibits NF-κB, but unlike these molecules ra-
ther than stimulating it inhibits mTOR in Capan1; con-
versely S100A9, unlike S100A8 and S100A8/A9, was less
inhibitory on Akt in Panc1. Intriguingly, NT-S100A8 and
TGFβ1 have shared effects on Akt and mTOR and, as re-
ported for S100 proteins, their effects are cell type
dependent: both molecules inhibited Akt Thr308, but not
Akt Ser473 phosphorylation in Smad4 expressing cells
(Capan1, MiaPaCa2 and Panc1) and activated mTOR in
all cell lines. Finally, TGFβ1 antagonizes the effects of
S100A8 on Akt Ser473 in MiaPaCa2 and Panc1 and thoseof S100A9 on mTOR in Capan1, but none of the NT-
S100A8 effects.
Smad4 deletion drives the NF-κB and Akt and reduces the
mTORC1 response to S100A8
In order to focus on Smad4 as a potential regulator of the
different effects induced by the same molecule in different
cell types, we studied BxPC3, which do not express
Smad4, and the stable transfected BxPC3-SMAD4+ cell
line. These two cell lines were treated with all the studied
molecules in the above-described conditions, and NF-κB,
Akt, mTOR and STAT signaling were then analyzed
(Additional file 5: Figure S5). Smad4 expression caused
a reduced IκBα phosphorylation after S100A8 treat-
ment, and a reduced Akt Thr308 phosphorylation after
S100A8/A9 treatment; these effects were not reverted
by TGFβ1. When Smad4 expression was restored in
BxPC3, it counteracted S100A8/A9, but not S100A8,
S100A9, NT-S100A8 or TGFβ1 induced mTOR Ser2481
phosphorylation. To further verify whether Smad4 im-
pacted on the effects of S100A8, NT-S100A8 and TGFβ1
on NF-κB, Akt and mTOR signaling, we analyzed IκBα,
Akt, mTOR and S6RP phosphorylation in MiaPaCa2,
which are Smad4 expressing cells, and in Smad4 silenced
MiaPaCa2 (Figure 7). In agreement with the hypothesis
deriving from BxPC3 and BxPC3-SMAD4+ findings that
Smad4 expression permits NF-κB inhibition, we found
that Smad4 silencing reduced the inhibition of NF-κB
after TGFβ1 and S100A8, but not after NT-S100A8 stimu-
lation. Moreover, silenced Smad4 markedly reduced S6RP





















































































































































































































































































Figure 4 Differential effects of S100 proteins and TGFβ1 on NF-κB signaling. BxPC3, Capan1, MiaPaCa2 and Panc1 remained unstimulated
(NC, negative control) or were stimulated for 10 min with 50 mU insulin (positive control), 0.02 ng/ml TGFβ1 alone or combined with 10 nM
S100A8, 10 nM S100A9, 10 nM S100A8/A9 complex, 50 nM NT-S100A8. Western blot show IκBα phosphorylation at Ser32 site and the corresponding
β-actin, used as the control. Histograms show semi-quantification of band intensities after normalization against the negative control (O.D.; ImageJ
software, v 1.47). Columns indicate mean values, bars indicate SD from two independ experiments.
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S100A8 or NT-S100A8 treatment which, in Smad4 silenced
cells, also induced mTOR, and reduced Akt Thr308 and
Ser473 phosphorylation.
The above data indicate that Smad4 is critically in-
volved not only in TGFβ1, but also in S100A8 and NT-
S100A8 signaling: these molecules preferentially activate
mTOR in wild type Smad4 expressing cells, while in
Smad4 negative cells S100A8 preferentially activates NF-
κB and mTOR while inhibiting Akt signaling.The effects and interactions of TGFβ1 and S100 proteins
in pancreatic cancer cell calcium flows
In order to ascertain whether TGFβ1 and S100 proteins
affect intracellular calcium, a key ion involved in the
regulation of multiple signaling pathways, the intracellu-
lar calcium concentration ([Ca2+]i) was monitored for
500 seconds while Flou4 fluorescence intensity was mea-
sured in two representative PDAC cell lines, BxPC3 and
MiaPaCa2. Figure 8 shows the BxPC3 data; each of the
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Panc1
Figure 5 Differential effects of S100 proteins and TGFβ1 on Akt signaling. BxPC3, Capan1, MiaPaCa2 and Panc1 remained unstimulated (NC,
negative control) or were stimulated for 10 min with 50 mU insulin (positive control), 0.02 ng/ml TGFβ1 alone or combined with 50 nM NT-S100A8,
10 nM S100A8, 10 nM S100A9, 10 nM S100A8/A9 complex. Western blot show the Akt phosphorylation sites Thr308 and Ser473 and the corresponding
non-phosphorylated Akt (panAkt), used as the control. Histograms show semi-quantification of band intensities after normalization against the negative
control (O.D.; ImageJ software, v 1.47). Columns indicate mean values, bars indicate SD from two independ experiments.
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did not determine evident alterations in [Ca2+]i, while
the S100A8/A9 complex caused a cascade of [Ca2+]ioscillations after 400 seconds (Figure 8I); this effect was
counteracted by TGFβ1 (Figure 8L). NT-S100A8 in-
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Panc1
Figure 6 Differential effects of S100 proteins and TGFβ1 on mTOR signaling. BxPC3, Capan1, MiaPaCa2 and Panc1 remained unstimulated
(NC, negative control) or were stimulated for 10 min with 50 mU insulin (positive control), 0.02 ng/ml TGFβ1 alone or combined with 50 nM
NT-S100A8, 10 nM S100A8, 10 nM S100A9, 10 nM S100A8/A9 complex. Western blot showed the mTOR phosphorylation sites Ser2481 and
Ser2448, the corresponding phosphorylation of S6 Ribosomal Protein at the Ser235/236 site (pS6RP) and β-actin, used as the control. Histograms show
semi-quantification of band intensities after normalization against the negative control (O.D.; ImageJ software, v 1.47). Columns indicate mean values,
bars indicate SD from two independ experiments.
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(Figure 8D). No variation in [Ca2+]i was observed in the
different experimental conditions investigated in Mia-
PaCa2. However, since an increasing or decreasing trend
in [Ca2+]i was observed in the different experimental
sets, we calculated the increment or decrement in [Ca2+]i
per minute per cell within a 200 to 480 second interval.
Figure 9 reports mean values and standard errors of
the percentage variations obtained in the differentexperimental sets (One-Way ANOVA: F = 12.17, p <
0.0001). TGFβ1, S100A8 and NT-S100A8 caused a signifi-
cant decrement of [Ca2+]i with respect to control cells.
The decrement induced by TGFβ1 was partly counter-
acted by S100A8 and S100A8/A9, and completely reverted
by S100A9. These data indicate that intracellular calcium
is altered by the S100A8, S100A9, S100A8/A9 heterocom-
plex and by NT-S100A8, these alterations being molecule-






































































Figure 7 (See legend on next page.)
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(See figure on previous page.)
Figure 7 Effects of Smad4 deletion on NF-κB, Akt and mTOR signaling. MiaPaCa2 (Control) and Smad4 silenced MiaPaCa2 (Smad4-siRNA)
remained unstimulated (NC, negative control) or were stimulated for 10 minutes with 0.02 ng/ml TGFβ1, 10 nM S100A8 or 50 nM NT-S100A8. Upper panels
show IκBα phosphorylation at Ser32 site and corresponding β-actin, used as the control. Middle panels show Akt phosphorylation sites Thr308 and Ser473 and
the corresponding non-phosphorylated Akt, used as the control. Lower panels show mTOR phosphorylation sites Ser2481 and Ser2448, and the S6 Ribosomal
Protein phosphorylation at Ser235/236 site. Histograms show semi-quantification of band intensities after normalization against the negative control (O.D.;
ImageJ software, v 1.47). Columns indicate mean values, bars indicate SD from two independ experiments. Black colomuns: MiaPaCa2
cells; white columns: Smad4-siRNA MiaPaCa2 cells.
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nized by S100A9; TGFβ1 appears to pave the way for NT-
S100A8-induced alterations in intracellular calcium.
TGFβ1 and S100 protein interactions and their effects on
cell proliferation, EMT and apoptosis
The proliferation of the four studied pancreatic cancer
cell lines was not influenced by S100A8, S100A9,
S100A8/A9 and/or TGFβ1 (Additional file 6: Table S1).
Combined stimulation with NT-S100A8 and TGFβ1 in-
duced an increase in MiaPaCa2 cell proliferation. We
then verified whether proliferation was Smad4 sensitive
by analyzing BxPC3 and BxPC3-SMAD4+ cell lines. As
shown in Additional file 7: Figure S6, Smad4 expression
was associated with a positive cell proliferation response
to TGFβ1 and NT-S100A8, alone or combined, but not
to the other molecules.
Since TGFβ1 is a strong promoter of the EMT, a crit-
ical step in carcinogenensis, we verified whether S100
calcium binding proteins are also involved in this
process. To do this we first performed the relative quan-
tification of Snai1, Snai2, Twist, Zeb1, Zeb2, CDH1 and
CDH2 mRNA expression of two representative PDAC
cell lines, BxPC3 and MiaPaCa2, with respect to the em-
bryonic human cell line HEK293; the results are re-
ported in Table 2.
EMT gene expression levels were then ascertained in
BxPC3 cells treated or untreated (control) with TGFβ1,
S100A8, S100A9, and the S100A8/A9 complex and NT-
S100A8. In BxPC3, TGFβ1 induced a 1.16 to 1.89 fold
increase in all EMT genes except for Twist, which had a
higher median fold increase (6.32 with respect to control
cells). The relative expressions of Snai1, Snai2, Zeb1,
Zeb2, CDH1 and CDH2 were not modified by S100 pro-
teins, whereas Twist expression was significantly in-
creased by S100A8 and by the S100A8/A9 complex to
levels comparable with those of TGFβ1 (Kruskal-Wallis
test: p = 0.018) (Figure 10A). The effects of TGFβ1,
S100A8 and S100A8/A9 on Twist expression were much
less evident when these molecules were simultaneously
added to the cell cultures (Figure 10A). These findings
were confirmed by those made at immunocytochemistry
(Figure 10B). The E-cadherin protein was not expressed
by untreated or treated BxPC3 cells. The findings for N-
cadherin are shown in Additional file 8: Figure S7.Untreated cells showed dishomogeneous non-continu-
ous membranous N-Cadherin immunostaining whereas
TGFβ1, S100A8, S100A9 and NT-S100A8 immunostain-
ing was less marked than in control cells. The S100A8/
A9 complex caused enforced moderate to complete
membranous immunostaining. When cells were co-
stimulated with TGFβ1 and S100A8 or S100A9, weak
complete immunostaining was observed. These data
confirm that TGFβ1 is an EMT inducer and that Twist
is its main target gene. Twist expression may also be en-
hanced by S100 calcium binding proteins but also by
NT-S100A8. The effects of TGFβ1, S100A8 and S100A9
on EMT are mutually antagonistic when these molecules
are added together.
To examine whether the studied molecules have pro-
apoptotic effects on PDAC cells, cleaved caspase-3 was
analyzed by western blot; this 17 kDa fragment was
hardly detected (detectable only in fragments) in both
control and treated Capan1, MiaPaCa2 and Panc1 cells.
Cleaved caspase-3, present in BxPC3, was unaffected by
any of the treatments (Figure 10C).
TGFβ1 and S100 proteins interact and form
heterocomplexes
In order to verify whether S100A8, S100A9 and TGFβ1
interact each other at a molecular level, these molecules
were mixed at a 1:1 molar ratio in the presence of Ca2+, in-
cubated overnight at room temperature and then analyzed
by MALDI-TOF/MS. S100A8 formed homo-dimers, while
S100A9 and TGFβ1 formed homo-dimers and homo-
trimers. S100A8 and S100A9 formed hetero-dimers not
only between themselves, but also with TGFβ1 (Figure 11).
MALDI-TOF/MS findings were confirmed by co-immunu-
noprecipitation experiments: TGFβ1 was detected in the
fraction of polypeptides eluted from S100A8- and S100A9-
Sepharose (Figure 11E and F, respectively). These data
clearly indicate that TGFβ1, S100A8 and S100A9 are part-
ner molecules.
Discussion
The levels of calcium binding proteins S100A8 and
S100A9 increase in cancer, including PDAC; although
mainly expressed by tumor-infiltrating inflammatory cells,
they may also be expressed by PDAC cells [31,34]. These
proteins are directly involved in piloting metastases by the
Figure 8 Intracellular calcium concentration ([Ca2+]i ) in BxPC3 cells. [Ca
2+]i was monitored for 500 seconds by epifluorescence after stimuli
(arrows). Each of the multiple lines in the graphs represent the [Ca2+]i of one cell. A: Control; B: TGFβ1; C: NT-S100A8; D: NT-S100A8 plus TGFβ1;
E: S100A8; F: S100A8 plus TGFβ1; G: S100A9; H: S100A9 plus TGFβ1; I: S100A8/A9; L: S100A8/A9 plus TGFβ1.
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Figure 9 Intracellular calcium ([Ca2+]i ) variations in MiaPaCa2
cells. Increment (from 0 to 1.5 y-axis) or decrement (from 0 to −1.5
y-axis) in [Ca2+]i per min per cell were calculated within a 200 to 480
second interval in the different experimental sets. Columns represent
mean values, and bars, standard errors. Bonferroni’s test for pairwise
comparisons: * = p < 0.05 with respect to the unstimulated cells;
** = p < 0.05 with respect to unstimulated and p < 0.01 with
respect to TGFβ1 stimulated cells.
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ter receptor, critical to bridging inflammation and cancer
[45], and its ligation, initiates a feed-forward loop that po-
tentiates inflammation, but may also favor the oncogenic
switch [24,30]. In agreement with the hypothesis that
S100A8 and S100A9 have a potential metastatic role,
S100A8 and S100A9 mRNA levels were almost undetect-
able in the primary BxPC3, MiaPaCa2 and Panc1, while
they were highly expressed by the metastatic SUIT2 and
Capan1 PDAC cell lines [46]. Further supporting the po-
tential role of S100A8/A9 proteins in metatases, high ex-
pression of their receptor, RAGE, was present not only in
metastatic Capan1, but also in the primary MiaPaCa2
cells, which cause a liver metastases rate overlapping that
of Capan1 [47]. The other S100A8/A9 receptor, TLR4
[29], is reported to activate STAT3 [48]. The finding that
this signal transducer was constitutively activated in allTable 2 EMT genes mRNA relative quantification in the
studied pancreatic cancer cell lines
BxPC3 MiaPaCa2 Hek293
Fold increase Fold increase Reference
Snai1 0.04 0.74 1
Snai2 0.11 2.06 1
Twist 0.48 × 10-3 0.38 × 10-3 1
Zeb1 0.12 0.32 1
Zeb2 0.87 × 10-3 Absent 1
CDH1 0.03 4.07 × 10-3 1
CDH2 0.04 Absent 1
Figure 10 EMT and apoptosis in BxPC3 cells. A: Twist mRNA
relative quantification of BxPC3 cells. Columns represent mean
values, and bars represent standard deviations. Bonferroni’s test for
pairwise comparisons: * = p < 0.05 with respect to non stimulated
cells; ** = p < 0.01 with respect to non stimulated cells. B: Twist
nuclear staining of BxPC3 cells. C: Western blot of cleaved caspase-3
(Casp-3) and β-actin, used as the control.PDAC cell lines, supports the hypothesis that it plays role
in this cancer type [49]; however the fact that it was not
induced by the S100 studied molecules, suggests that they
act mainly through RAGE engagement.
Figure 11 S100A8, S100A9 and TGFβ1 molecular interactions. S100A8, S100A9 and TGFβ1 and calcium ions (CaCl2) were mixed at an
equimolar concentration (11.3 μM) in an aqueous solution, incubated overnight at 37°C and then submitted for MALDI-TOF/MS analysis. A:
S100A8 alone; B: S100A9 alone; C: S100A8 and S100A9; D: S100A8, S100A9 and TGFβ1; E: TGFβ1 was incubated overnight at an equimolar
concentration (1.6 μM) with S100A8 and CaCl2 at 37°C. Immunoprecipitation (IP) was performed using anti-S100A8. The immunoprecipitate
underwent western blotting (WB) for the detection of TGFβ1. F: TGFβ1 was incubated overnight at an equimolar concentration with S100A9 and
CaCl2 at 37°C. Immunoprecipitation (IP) was performed using anti-S100A9. The immunoprecipitate underwent western blotting (WB) for
TGFβ1 detection.
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is enriched by the biologically active N-terminal 14 aa
fragment of S100A8 (NT-S100A8) [34]. In this study, in
order to further exploit tumor stoma interactions, we
first verified whether tumor cells release solublemediators able to fragment the S100A8 protein. Since
the 12–15 aminoacid sequence IIDV of S100A8 fits with
the group II consensus motif (L/IXX | XHy) of MMP2
[50], we ascertained whether MMPs have a role in causing
the release of NT-S100A8. In the presence of PDAC -
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lecular weight peptides, which were more abundant at
2280 m/z. At MS/MS analysis, the 2280 m/z peptide
was found to correspond to the N-terminal 19 aa se-
quences of the original S100A8 protein, this being five
aa longer than the PDAC-associated NT-S100A8 peptide
[34]. The assumption that PDAC-derived MMPs might
be responsible for S100A8 fragmentation and delivery of
the 2280 m/z peptide was supported by the finding that
S100A8 was not fragmented by conditioned media ob-
tained from cells treated with Ukrain, which downregu-
lates the activities of MMPs [41]. In the presence of
PDAC cell conditioned media, the 2280 m/z peptide was
resolved in two main degradation products at 1435 and
1030 m/z, which encompass the 8–19 and the 2–10
S100A8 aminoacid sequence, but also in a fragment at
1852 m/z, encompassing the 1–16 N-terminal aminoacid
sequence of S100A8, which is very close to the NT-
S100A8. This peptide was also detected when the entire
S100A8 was incubated with Capan1 conditioned media,
thus confirming that it derives from PDAC induced pro-
teolytic cleavage of this calcium binding protein. Both
BxPC3 and Capan1 conditioned media equally processed
the 2280 m/z peptide, but the kinetics were different:
metastatic Capan1 cells caused a more rapid (2 hours)
degradation of the parental 2280 m/z peptide than the
poorly metastatic BxPC3 cells (12 hours), and this indi-
cates that PDAC cells, depending on their metastatic po-
tential, produce different amounts of the same S100A8
targeting proteases. PDAC-associated S100A8 degrad-
ation may be governed by a regulatory mechanism
restricting its function, but the release of peptides with
their own biological activity might circumvent this
phenomenon and modify tumor biology. We therefore
studied the effects of S100A8, S100A9 and the S100A8/
A9 complex, but also of NT-S100A8, on critical aspects
of tumor biology, namely intracellular signaling, cell pro-
liferation and EMT. On investigating NF-κB, Akt and
mTOR signaling, we found that all these signaling path-
ways are differently targeted by S100A8, S100A9 and
NT-S100A8 depending on the PDAC cell type (results
summarized in Additional file 9: Figure S8). In PDAC
cells with intact Smad4 (Capan1, MiaPaCa2 and Panc1),
S100A8, S100A9 and S100A8/A9 shared an overall in-
hibitory effect on NF-κB, while these molecules did not
affect NF-κB in the presence of SMAD4 homozygous
deletion (BxPC3 cells). It has recently been suggested
that NF-κB activation in PDAC is closely involved in
driving tumor progression, especially when its activation
is sustained, and that it plays a key role in linking in-
flammation and cancer [51]. Our findings suggest that
S100 proteins, by targeting NF-κB signaling, may coun-
teract cancer progression in Smad4 positive, but not in
Smad4 negative, PDAC. However, other intracellularpathways, such as Akt, are critically involved in cancer
proliferation, angiogenesis and metastases [43]. The two
Akt activation sites, Thr308 and Ser473, were de-
phosphorylated by S100A8, S100A9 and S100A8/A9 in
Smad4 expressing cells, while Akt Thr308 was activated
and Ser473 unaffected by all these molecules in Smad4
negative BxPC3 cells.
Overall, the above data suggest that Smad4 deletion is
permissive for S100A8/A9 activation of NF-κB and Akt
signaling pathways in PDAC cells. Interestingly, NT-
S100A8 was far from ineffective and had effects similar
to those of its parent molecule S100A8: the phosphoryl-
ation grade of the Akt Thr308 site was induced in BxPC3,
and reduced in Capan1 and MiaPaCa2. In the PDAC set-
ting, therefore, the degradation of S100A8 does not abol-
ish its biological effects on PDAC cells, its NT-S100A8
proteolytic fragment maintaining them.
Akt signaling depends on a complex relationship with
mTOR signaling: Akt activates mTOR complex 1
(mTORC1), while mTORC2 phosphorylate Akt on the
hydrophobic motif Ser473 [43]. However, in human
PDAC, mTOR phosphorylation was more closely associ-
ated with cancer cells than Akt phosphorylation, which
was found in the neoplastic ducts, but also in acinar,
islet and stroma cells [52]. We therefore ascertained
whether S100 proteins affected mTOR. As the catalytic
subunit of the two distinct complexes, mTORC1 and
mTORC2 [53], mTOR was sensitive to S100A8, which
induced in BxPC3, Capan1 and MiaPaCa2 Ser2481 phos-
phorylation. Interestingly, the S100A9, but above all the
S100A8/A9 complex, have opposite effects on mTOR:
they induced mTOR phosphorylation in BxPC3, Mia-
PaCa2 and Panc1 and reduced it in Capan1. NT-S100A8
induced mTOR Ser2481, but also Ser2448 phosphorylation
in almost all PDAC cell lines. Overall, our findings sup-
port the hypothesis that S100A8, S100A9 and NT-
S100A8 are Janus-faced molecules [28] that can have
pro- and anti-cancer effects, depending on the cellular
context. Since the four cell lines studied differ in their
differentiation grade but also have distinct genetic aber-
rations, Smad4 in particular [42,54], our hypothesis was
that opposite responses to the same S100 molecule in
different cell lines might depend on Smad4 status. To
verify this, we selected cell without (BxPC3) and with
(MiaPaCa2) Smad4 expression. BxPC3 were compared
with BxPC3-SMAD4+ cells and MiaPaCa2 were com-
pared with Smad4-siRNA-transfected MiaPaCa2 cells.
Our findings confirmed that S100A8 does not inhibit or
even activate NF-κB in the absence of Smad4 expression,
but also supported the observation that S100A8 and
NT-S100A8 activate mTOR independently from Smad4
status. Since Smad4 is critically involved in TGFβ1 sig-
naling, it is reasonable to assume that there is a close
link between these calcium binding proteins and TGFβ1
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bined effects of TGFβ1 and S100A8, S100A9, S100A8/
A9 and NT-S100A8. TGFβ1 partly counteracted the ef-
fects of S100 proteins on NF-κB and Akt signaling in
cells with Smad4 expression, but not those on mTOR.
The effects of NT-S100A8 on Akt and mTOR, not those
on NF-κB, were very similar to those exerted by S100A8,
but were almost completely equal to those of TGFβ1
thus suggesting that NT-S100A8 might be functionally
considered a TGFβ1-like molecule. The functional simi-
larity between NT-S100A8 and TGFβ1 was also found
when their effects on cell growth were evaluated. These
two molecules synergistically stimulated the growth of
MiaPaCa2 cells, but also the growth of BxPC3-SMAD4+,
not that of BxPC3 cells, suggesting that this synergistic
pro-proliferative effect is Smad4 dependent.
S100A8, S100A9, NT-S100A8 and TGFβ1 interactions
were also found on intracellular calcium, which was
analyzed because a crosstalk between calcium signaling
and proliferation pathways has been well documented
[35,37,38,55]. TGFβ1 accelerated the rapid train of intracel-
lular calcium oscillations evoked by NT-S100A8 in BxPC3;
this further supports the notion that these two molecules
share effects and act in co-operation. Like NT-S100A8, the
heterocomplex S100A8/A9, not any single molecule, evoked
a sequence of intracellular calcium oscillations but, in the
latter case, TGFβ1 counteracted the observed effect rather
than reinforcing it. In MiaPaCa2, NT-S100A8 and S100A8
caused a reduction in intracellular calcium, and TGFβ1 had
a similar effect. Importantly, S100A9 reversed the effects of
TGFβ1, this finding further supporting the hypothesis that
interactions may occur between TGFβ1 and S100 proteins.
In view of the interactions between S100 proteins and
TGFβ1, and the fact that TGFβ1 is a well known inducer
of EMT, a relevant biological phenomenon in morpho-
genesis and in cancer initiation and progression, we
ascertained whether the observed molecular interactions
also occur in this process. Of the two cell lines studied,
the less differentiated and more aggressive MiaPaCa2
cell line expressed EMT genes at a level comparable to
that of embryonic cells, suggesting a pre-existent EMT
process. We therefore studied the more differentiated
BxPC3 cells that, unlike the other cell lines, constitu-
tively expressed cleaved caspase-3. However, none of the
molecules studied induced this apoptotic marker.
TGFβ1, as expected, induced an increased expression of
all the EMT markers studied, while the S100 proteins in-
duced only Twist mRNA expression, although in a dif-
ferent manner. The main inducers were the S100A8 and
the S100A8/A9 complex, and these findings were con-
firmed at immunocytochemistry.
Since it has been claimed that Twist is involved not
only in EMT, but also in inhibiting p53 mediated apop-
tosis, in the acquired resistance of cancer cells tochemotherapy and in circumventing oncogenic k-ras
mediated cellular senescence [56,57], our results further
indicate a link between the inflammatory S100 mole-
cules and cancer progression. The effects of TGFβ1 and
S100A8 on Twist expression were not cumulative, being
reduced when both substances were added together, and
S100A9, once again, counteracted the effects of TGFβ1.
Interestingly, TGFβ1, but also S100A9 and NT-S100A8
reduced the membrane expression of N-Cadherin, while
these effects were less pronounced when cells were co-
stimulated with TGFβ1 and S100A9 or NT-S100A8.
All the above-described functional interactions may be
due to different factors, including the sharing of co-
receptors, and receptor interactions, but they might also be
due to complex interactions between S100A8/A9 proteins
and other molecules, like those occurring between S100A4
and amphiregulin [58] or S100B and basic fibroblast
growth factor [59,60]. These interactions might prevent the
canonical RAGE engagement by S100A8/A9 and enhance
signaling of other receptors, like those of the interacting
molecules, as demonstrated to occur when S100B interacts
with βFGF [60]. We demonstrated by MALDI-TOF/MS
and co-immunoprecipitation that TGFβ1 not only forms
homo-dimers, but also homo-trimers and that this is true
also for S100A9 (not shown), while S100A8 appears to al-
most exclusively form homo-dimers. It was confirmed that
S100A8 and S100A9 form hetero-dimers but, as hypothe-
sized, TGFβ1 was able to form hetero-complexes with both
S100 molecules. In vivo, these interactions, occurring at the
tumor stroma interface, probably contribute in the balance
between the reported pro- and anti-tumor effects of
S100A8/A9 in PDAC and further investigations of this
phenomenon might allow the identification of new poten-
tial targets for intervention.
Conclusions
In this study we demonstrated that in the PDAC setting
important interactions occur between the calcium binding
proteins S100A8 and S100A9 and TGFβ1. PDAC cells de-
rived proteases target the inflammatory S100A8 protein
causing the release of small peptides. One of these peptides,
NT-S100A8, is biologically active and was demonstrated to
exert TGFβ1-like effects on PDAC cell NF-κB, Akt and
mTOR signaling and to synergize with TGFβ1 in altering
intracellular calcium and in stimulating cell proliferation.
Smad4 status affects S100A8 signaling, favoring mTORC1
when expressed and NF-κB when deleted. S100A9, by
binding TGFβ1, counteracts the effects of this molecule on
intracellular calcium, signaling and the EMT process.
Materials and methods
Cell lines
The pancreatic cancer cell lines used were: Panc1 and
Suit2, donated by Prof Aldo Scarpa (University of
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Florence, Italy); MiaPaCa2, Capan1 and the human embry-
onic kidney Hek293 cell lines, supplied by the American
Type Culture Collection (Manassas, VA, USA). BxPC3,
Capan1 and Panc1 were cultured in RPMI (Gibco/BRL,
Gaithhersburg, MD, USA) supplemented with 10% (BxPC3
and Panc1) and 20% (Capan1) fetal calf serum (FCS)
(Gibco/BRL), 1% L-glutamine (Gibco/BRL) and 0.1% genta-
mycin (Gibco/BRL). MiaPaCa2 and Hek293 were cultured
in DMEM (Gibco/BRL) supplemented with 10% FCS, 2% L-
glutamine and 0.1% Gentamycin. BxPC3 cells were trans-
fected with the expression vector pBK-cytomegalovirus
(CMV)-SMAD4/DPC4, as previously described [34]. One
SMAD4/DPC4-expressing clone (BxPC3-SMAD4+) was
used for the experiments. Smad4 silencing of MiaPaCa2
cells was performed as previously described [61].
Culture media for S100A8 proteolysis assay
To obtain BxPC3 and Capan1 conditioned media (CM),
400,000 cells were cultured (75 cm2 flasks) for 96 hours in
RPMI supplemented with 1% FCS and 0.1% gentamycin.
In parallel, Ukrain (Nowicky Pharma, Wien, Austria)
treated Capan1 CM were obtained as above, the difference
being that Ukrain was added 24 hours after cells had been
seeded at the final concentration of 5 μM. Complete cul-
ture media maintained in a cell culture incubator for
96 hours (negative control), Capan1 and Ukrain-treated
Capan1 CM were centrifuged at 1,500 rpm for 10 min,
and then immediately mixed with 3 μM S100A8 or
2.5 μM S100A9 (ProSpec-Tany TechnoGene, Ness Ziona,
Israel) and maintained at 37°C overnight before MALDI-
TOF/MS analyses. Complete culture media, BxPC3 and
Capan1 CM, treated as described above, were incubated at
37°C with 200 μM of the S100A8 1–19 N-terminal ami-
noacid sequence (NT-S100A8) (Primm, Milano, Italy) for
1, 2, 3, 4, 5, 6, 12 and 24 hours before MALDI-TOF/MS
analyses. At least three independent sets of experiments
were performed for both assays.
Sample preparation for immunoblot analysis
Five million cells were seeded in Petri dishes (ø 10 cm)
and cultured for 24 hours in their respective complete
media prior to starting the experiments. Cells remained
non-stimulated (negative control) or were stimulated
with 50 mU insulin (positive control) (Insuman Rapid,
Sanofi-Aventis, Deutschland, GmbH) for 10 min; in par-
allel, experimental cells were stimulated with 50 nM
NT-S100A8, 0,02 ng/ml TGFβ1 (ProSpec-Tany Techno-
Gene), 10 nM S100A8 and 10 nM S100A9 alone or
combined for 10 min. Following stimulations, Petri
dishes were immediately transferred into an ice bath,
and the cells were washed twice with cold PBS, re-
suspended in 100 μl of cold lysis buffer [20 mM Tris–
HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton-X100, 50 mM NaF, 10 mM Na4P2O7,1 mM Na3VO4, and
10% protease inhibitor cocktail (Sigma Aldrich SRL, Mi-
lano, Italy)]. Lysates were centrifuged for 10 min at
14,000 rpm at 4°C and, in the supernatants, total pro-
teins were measured using the Bio-Rad protein assay
(Bio-Rad Laboratories, Milano, Italy). Each experiment
was performed at least in triplicate.
Immunoblot analysis and co-immunoprecipitation
For each sample, 40 μg proteins were electrophoresed
through 4–12% NuPAGE®NovexBis-Tris SDS–PAGE Gel
or 3-8% NuPAGE®NovexTris-Acetate SDS–PAGE Gel
(Invitrogen S.R.L., Life Technologies, Monza, Italy) and
electrophoretically transferred to Nitrocellulose Mem-
brane (iBlot® Transfer Stack, Invitrogen S.R.L.) by means
of the iBlotTMDry Blotting System (Invitrogen S.R.L.).
Following incubation for 1 hour in a blocking buffer [5%
low fat powder milk re-suspended in PBS-T (PBS with
0.1% Tween-20)], membranes were incubated overnight
at 4°C with the primary antibodies [antiphospho IkB-α
(Ser32) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
USA); anti-phospho-Akt (Ser473), anti-phospho-Akt
(Thr308), anti-Akt and anti-phospho-S6 Ribosomal Pro-
tein (Ser235/236), anti-cleaved Caspase-3, anti-phospho-
Stat3 Tyr705, anti-β-actin, anti-phospho mTOR (Ser2448,
Ser2481) (Cell Signaling Technology, Danvers, MA, USA);
anti-RAGE (R&D Systems, Minneapolis, MN, USA) ] di-
luted 1:5000 (β-actin), 1:2000 (mTOR, cleaved Caspase-3,
Stat3) or 1:3000 (all the others) in the blocking buffer. The
blots, washed three times in PBS-T for 15 min, were incu-
bated with alkaline phosphatase-conjugated anti-rabbit
(Cell Signaling Technology) or anti-goat (Sigma Aldrich)
secondary antibodies and then washed three times in
PBS-T for 15 min and developed with the ECL Advance
Western Blot Detection Kit (GE Healthcare Technologies,
Milan, Italy).
Co-immunoprecipitation experiments were performed
using protein G-Sepharose (GE Healthcare Technologies).
TGFβ1 (1.6 μM) was incubated in equimolar concentrations
with S100A8 or S100A9 at 37°C overnight in the presence
of equimolar CaCl2. The mixtures were then incubated for
2 h with anti-S100A8 polyclonal or anti-S100A9 monoclonal
antibodies (Santa Cruz Biotechnology) preadsorbed to pro-
tein G. Immunoprecipitates, washed three times in 10 mM
Tris HCl containing 40 mM NaCl, pH 7.5, were boiled in an
SDS-PAGE sample buffer before electrophoresis on 4–12%
NuPAGE®NovexBis-Tris SDS–PAGE gels. After protein
transfer, nitrocellulose membranes were blotted with anti-
TGFβ1 antibody (Cell Signaling Technology).
Effects of S100A8, S100A9, NT-S100A8 and TGFβ1 on
BxPC3 and MiaPaCa2 intracellular calcium ([Ca2+]i)
BxPC3 and MiaPaCa2 cells, seeded (80 × 103 cells) on
coverslips that had been inserted within each well of six
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complete media for 24 hours. Coverslips were then incu-
bated for 10 min at 37°C with 3 μM fluo-4 AM (Invitro-
gen S.R.L.) in an imaging buffer containing 137 mM
NaCl, 5 mM KCl, 1.2 mM MgCl2, 0.44 mM KH2PO4,
4.2 mM NaHCO3, 5 mM glucose, and 20 mM HEPES
pH 7.4. The cells were carefully washed with the imaging
buffer after its removal. Calcium oscillations were then
analyzed by means of an inverted epifluorescence micro-
scope equipped with a top stage incubator (Tokai Hit
INU-F1, Tokai Hit, Shizuoka-Ken, Japan) in order to
keep cells in the optimal culturing environment. As an
illumination source, we used a mercury arc discharge
lamp and selected excitation and emission wavelengths
with an FITC filter cube (EX 465–495 DM505 EM 515–
555 nm). Use was made of an 60X1.45NA objective
(Nikon Instruments S.P.A., Firenze, Italy) and, in order
to minimize phototoxicity and photobleaching, a back-
thinned electron multiplied CCD camera C9100-13 Ima-
gem (Hamamatsu Photonics Italia S.R.L., Milano, Italy).
After the first minute, required to achieve optimal cul-
ture conditions, intracellular fluorescence was continu-
ously monitored (3 frames/sec) for 12 min. In all
experiments, during the first minute of recording, the
cells were maintained in imaging buffer for the first 2 mi-
nutes, after which they were stimulated with 10 nM
S100A8, 10 nM S100A9 and 50 nM NT-S100A8, alone
or in combination with 0.02 ng/ml TGFβ1. For all stim-
uli, additions were made directly to the microscope
chamber without interrupting the recording. The fluor-
escence signal was quantified by measuring the mean
pixel value of a manually selected cellular area for each
frame of the image stack using the HCimage system
(Hamamatsu Photonics Italia S.R.L.). For all the experi-
mental conditions, at least 3 independents sets of experi-
ments were performed.
Real time PCR (RT-PCR) for EMT markers
BxPC3 and MiaPaCa2 cells (300 × 103) were seeded in six
well dishes for 24 hours in their complete media. Cells
remained non-stimulated (negative control) or were
stimulated with 10 nM S100A8, 10 nM S100A9 and 50
nM NT-S100A8, alone or combined with 0.02 ng/ml
TGFβ1, for 72 hours. Following stimulation, the cells
were collected with 0.25% trypsin (1 mM EDTA) and
centrifuged for 10 min at 4,000 rpm. Total RNA was ex-
tracted from cells using the High Pure RNA isolation kit
(Roche, Monza, Italy), and reverse transcription was per-
formed using 200 ng of total RNA, M-MLV Transcript-
ase and 250 μM random primers (Invitrogen S.R.L.).
Quantitative Real-Time PCR analysis for CDH1 (E-cad-
herin), CDH2 (N-cadherin), SNAI1 (Snail), SNAI2
(Slug), TWIST1 (Twist), ZEB1, ZEB2, and B2M (β2-mi-
cro-globulin) were performed with the LightCycler 480Real-Time System (Roche Diagnostics, Mannheim,
Germany). The primer sequences (shown in Additional
file 10: Table S2) and the respective probes were de-
signed using the Universal ProbeLibrary (Roche) and
ProbeFinder software (http://www.roche-applied-science.
com/). Experimental procedures followed the standard
protocol using the LightCycler 480 Probes Master
(Roche). β2-microglobulin (B2M) was included as a
housekeeping gene control. At least three independent
sets of experiments were performed in each experimen-
tal condition, and all real time PCR reactions were run
in triplicate.
Immunocytochemistry
In order to investigate immunocytochemical reactions,
control and stimulated cells were formalin-fixed and
paraffin embedded before obtaining 4–5 mm-thick sec-
tions from each cell block. All immunocytochemical
staining was performed automatically (Bondt—maX,
Menarini, Florence, Italy) with primary antibodies: E-
cadherin (DakoCytomation, Glostrup, Denmark) (1:200),
N-cadherin (DakoCytomation) (1:100), Twist1 (Novocas-
tra, Newcastle-upon-Tyne, UK)(1:600). Sections were
then lightly counterstained with hematoxylin. E-cadherin
and N-cadherin immunoreactions were defined as
immunoreactions detectable in the membrane while
Twist was defined as a positive nuclear staining. At least
three independent sets of experiments were performed
in each experimental condition.
MALDI-TOF/MS reflectron positive ion mode analysis
Cell culture media were first desalted and purified by
ZipTip C18 pipette tips, following the procedure de-
scribed in the ZipTip user’s guide. Five microliters of
each purified peptide solution were added to 5 μl of α-
cyano-4-hydroxycinnamic acid (HCCA) and 1 μl of the
resulting mixture was deposited in duplicate on the steel
sample holder and allowed to dry. MALDI-TOF/MS
measurements were performed using an Ultraflex II
MALDI-TOF instrument (BrukerDaltonics, Bremen,
Germany), operating in reflectron positive ion mode.
Ions were formed using a pulsed UV laser (λ = 337 nm)
beam. The instrumental conditions were: IS1 = 25 kV;
IS2 = 21.65 kV; reflectron potential = 26.3 kV; delay time =
0 nsec. External mass calibration (Peptide Calibration
Standard, BrukerDaltonics) was based on monoisotopic
values of [M+H] + of Angiotensin II, AngiotensinI, Sub-
stance P, Bombesin, ACTH clip (1–17), ACTH clip (18–39),
Somatostatin 28 at m/z 1046.5420, 1296.6853, 1347.7361,
1619.8230, 2093.0868, 2465.1990 and 3147.4714, respectively.
MALDI-TOF/MS linear positive ion mode analysis
S100A8, S100A9 and TGFβ1 and calcium ions (CaCl2)
were mixed at an equimolar concentration (11.3 μM) in
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night at 37°C prior to MALDI-TOF/MS analysis. S100A8,
S100A9 and TGFβ1 mixtures were diluted 1/10 in 50 μL
of 0.1% TFA aqueous solution, after which 5 microliters of
each dilution were added to 5 μl of Sinapinic acid (SA);
1 μl of the resulting mixture was deposited in duplicate on
the steel sample holder and allowed to dry. External mass
calibration (Protein Calibration Standard II, BrukerDal-
tonics) was based on monoisotopic values of [M +H] + of
Trypsinogen, Protein A, Albumin-Bovine (BSA), at m/z
23982, 44613, 66500, respectively. MALDI-TOF/MS mea-
surements were performed using an Ultraflex II MALDI-
TOF instrument (BrukerDaltonics), operating in linear
positive ion mode. Ions were formed using a pulsed UV
laser (λ = 337 nm) beam. The instrumental conditions
were: IS1 = 25 kV; IS2 = 23.35 kV; delay time = 70 nsec. All
chemicals and solvents were purchased from Sigma-
Aldrich (Sigma Aldrich). One spectrum was collected for
each sample, an average of 1,000 laser shots being ob-
tained from the respective two replicate spots.
Statistical analysis
The statistical analysis of data was made using one-way
analysis of variance (ANOVA), Bonferroni’s test for pair-
wise comparisons, and Mann Whitney and Kruskal
Wallis tests using the statistical software SPSS version 9.
Additional files
Additional file 1: Figure S1. Receptor for advanced glycation
endproducts (RAGE) in PDAC cell lines. A) Western blot results obtained
from PDAC cell lines (five millions in ø 10 cm Petri dishes) cultured for 24
hours in their respective complete media. Immunoblot was performed as
described in Materials and Methods using Anti-RAGE (R&D Systems, USA)
at a 1:200 dilution. B) Columns show the mean optical densities (O.D.;
ImageJ software, v 1.47) of RAGE immunoblot results, obtained from
5 independent experiments. Bars show standard deviations.
Additional file 2: Figure S2. MALDI-TOF-MS/MS sequencing of the
2280 m/z peptide. S100A8 was incubated with Capan1 conditioned
media for 48 hours at 37°C before MALDI-TOF-MS/MS sequencing of the
degration peptide at 1435 m/z. De novo sequencing was obtained by
Mascot Distiller (v 2.5.0.0).
Additional file 3: Figure S3. MALDI-TOF-MS/MS sequencing of the
1435 m/z peptide. S100A8 was incubated with Capan1 conditioned
media for 48 hours at 37°C before MALDI-TOF-MS/MS sequencing of the
degration peptide at 1435 m/z. De novo sequencing was obtained by
Mascot Distiller (v 2.5.0.0).
Additional file 4: Figure S4. Differential effects of S100 proteins and
TGFβ1 on STAT signaling. BxPC3, Capan1, MiaPaCa2 and Panc1 remained
unstimulated (NC, negative control) or were stimulated for 10 minutes
with 50 mU insulin (positive control), 0.02 ng/ml TGFβ1 alone or
combined with 50 nM NT-S100A8, 10 nM S100A8, 10 nM S100A9, 10 nM
S100A8/A9 complex. Western blot shows Stat3 phosphorylation at Tyr705
site and the corresponding β-actin, used as control. Histograms show
semi-quantification of band intensities after normalization against the
negative control (O.D.; ImageJ software, v 1.47). Columns indicate mean
values, bars indicate SD from two independ experiments.
Additional file 5: Figure S5. Differential effects of S100 proteins and
TGFβ1 on NF-κB, Akt, mTOR and STAT signaling in Smad4 expressing
BxPC3 cells. BxPC3-SMAD4+ cells remained unstimulated (NC, negativecontrol) or were stimulated for 10 minutes with 50 mU insulin (positive control),
0.02 ng/ml TGFβ1 alone or combined with 50 nM NT-S100A8, 10 nM S100A8,
10 nM S100A9, 10 nM S100A8/A9 complex. A: IκB-α phosphorylation at Ser32
site and corresponding β-actin. B: Akt phosphorylation sites Thr308 and Ser473
and corresponding non-phosphorylated Akt (panAKT). C: mTOR phosphorylation
sites Ser2481 and Ser2448, phosphorylation of S6 Ribosomal Protein at the Ser235/236
site (pS6RP) and β-actin. D: Stat3 phosphorylation at Tyr705 site and corresponding
β-actin. Histograms show semi-quantification of band intensities after normalization
against the negative control (O.D.; ImageJ software, v 1.47). Columns indicate mean
values, bars indicate SD from two independ experiments.
Additional file 6: Table S1. XTT cell viability assay results.
Additional file 7: Figure S6. XTT cell viability assay results. BxPC3
(empty columns) and BxPC3-SMAD4+ (filled columns) were seeded in a
96 well culture plate (2000 cells/well) and cultured for 48 hours, A: in absence
(control) or in presence of TGFβ1 (0.02 ng/ml) and NT-S100A8 (50 nM), alone
or combined; B: in absence (control) or in presence of TGFβ1 (0.02 ng/ml) and
S100A8 (10 nM) and S100A9 (10 nM), alone or combined. In each experimental
set, the median value of Abs450nm of untreated cells was calculated and used
as reference. All the other values were expressed as percentage to the reference.
Columns and bars show mean and standard errors, respectivelty. Student’s t test:
* = p<0.05.
Additional file 8: Figure S7. N-cadherin immunostain. BxPC3 cells
treated with NT-S100A8, S100A8, S100A9, S100A8/A9 alone (left panels)
or combined (right panels) with TGFβ1.
Additional file 9: Figure S8. Schematic representation of results. This
study demonstrates that metastatic PDAC cells express S100A8/A9 mRNA
transcripts and that both primary and metastatic PDAC-derived proteases
cause the release of small peptides from the N-terminal sequence of
S100A8. S100A8, S100A9 and S100A8/A9 heterocomplex share many
effects on NF-κB, Akt and mTOR signaling in PDAC cells and these effects
are dependent on SMAD4 expression (Smad4+=Smad4 expressing PDAC
cells; Smad4- = Smad4 non expressing PDAC cells). The effects of the 14
aminoacid N-terminal sequence of S100A8 (NT-S100A8) may overlap
those of the entire S100A8 or may differ. Continuous arrows indicate
stimulation, dotted arrows indicate inhibition, dotted lines indicate no
effect. TGFβ1 may counteract S100 proteins effects on NF-κB or Akt in
SMAD4+, not in SMAD4-, PDAC cells. “Yes” indicates that TGFβ1
counteracts, “No” indicates that TGFβ1 does not counteract that specific
effect of S100 proteins. *: only in Capan1 cell line.
Additional file 10: Supplementary Materials and Methods. Table S2.
Primers used for qRT–PCR analysis of the EMT genes.
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